Summary

The results of several Gynecologic Oncology Group (GOG) trials have established doublet chemotherapy with standard-dose cisplatin and paclitaxel as the preferred treatment for advanced or recurrent cervical cancer. The GOG 204 trial [NCT00064077] was conducted to evaluate 3 experimental cisplatin-containing doublet chemotherapy regimens against the standard of cisplatin and paclitaxel.